Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKONEX 2961601 approvals6 trials

ProGen, Co,, LTD.

Official website

KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®

As of 2026-10-10, ProGen, Co,, LTD. has 1 Korean MFDS device approval, 12 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1998 and listed on KONEX in 2023, ProGen is a biotech venture built on its multi-target fusion protein platform NTIG®. Flagship candidate PG-102 for obesity/diabetes is in Phase 2, oral drug RPG-102 is in Phase 1; its earlier hyFc® platform was applied to EPO, GH, GLP-1 and IL-7. IgE Trap was licensed to GI Innovation for KRW 18.25 billion, and NTIG® was also licensed to Genexine.

Regulatory approvals

data.go.kr

1 Korean MFDS device approvals · 2013

  • MFDSreagents for clinical enzymesRevoked2013-12-20
    Product approval · Class 2수허 13-3416 호

Clinical trials

data.go.kr

6 MFDS clinical trial authorisations · 2023–2026 (Phase 1 3 · Phase 2 3)

  • Phase 1PG-1022026-07-13

    1 trial site

  • Phase 2PG-1022026-05-18
  • Phase 2PG-1022026-02-26

    5 trial sites

  • Phase 2PG-1022024-07-05

    13 trial sites

  • Phase 1PG-1022023-08-07

    1 trial site

  • Phase 1GX-1702023-02-07

    3 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

PG-102 · 비만 및 당뇨질환 · 임상2상 · Flagship program applying the NTIG® multi-target fusion protein platform

RPG-102 · 비만(경구) · 임상1상 · Oral obesity treatment candidate

근육보존제 및 면역질환 치료제 후보물질 · 근육보존/면역질환 · 디스커버리/비임상 · Early-stage pipeline pursued through domestic and overseas open innovation

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 2 more publications

Patents

KIPRIS · applicant-matched
Show 56 more patents

AI reads

MAA server logs · IP-verified
116
Times AI engines pulled ProGen, Co,, LTD.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

113
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

14
live 1
Last 7 days
59
live 2
Last 30 days
116
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot58
  • GoogleGoogleOther42
  • PerplexityPerplexityBot10
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for ProGen, Co,, LTD. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · products. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Boditech Med Inc.1 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

Hanmi Science Co.,Ltd1 shared

KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.

HUMASIS CO., LTD.1 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

OSANG HEALTHCARE CO.,LTD.1 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

PCL. Inc1 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

Access Bio, Inc.1 shared

Founded in 2002 and KOSDAQ-listed in 2013, Access Bio develops rapid diagnostic tests for malaria, COVID-19, and other infectious diseases.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

TASCOM Co.,Ltd.1 shared

Develops SimplexTAS, a point-of-care clinical chemistry and immunoassay analyzer for IVD testing.

GENEMATRIX INC.1 shared

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

DONG-A ST CO.,LTD1 shared

Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition